-
New Issue Published Combinatorial Chemistry & High Throughout Screening Vol. 21 Issue 3 -
New Issue Published Letter in Drug Design & Discovery Vol. 15 Issue 1 -
New Issue Published Letter in Drug Design & Discovery Vol. 15 Issue 6 -
New Issue Published Letter in Drug Design & Discovery Vol. 15 Issue 5 -
Most Accessed Article : In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC... -
Podcast for (Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol)
-
New Issue Published Letter in Drug Design & Discovery Vol. 24 Issue 3 -
New Issue Published Letter in Drug Design & Discovery Vol. 14 Issue 12 -
Free Online Issue of Letters in Drug Design & Discovery
PD-0325901 i a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. PD-0325901
ReplyDelete